LPH-5 (drug)
Psychedelic drug
From Wikipedia, the free encyclopedia
LPH-5, also known as (S)-3-(2,5-dimethoxy-4-(trifluoromethyl)phenyl)piperidine or as (S)-2C-TFM-3PIP, is a psychedelic drug of the phenethylamine, 2C, and 3-phenylpiperidine families which is under development for potential medical use.[1][2][3][4][5] It is a cyclized phenethylamine and is the derivative of 2C-TFM in which the β position has been connected to the amine to form a piperidine ring.[1][2][3]
- None
- In general unscheduled
 | |
| Clinical data | |
|---|---|
| Other names | (S)-3-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)piperidine; (S)-2C-TFM-3PIP; (S)-β,N-Trimethylene-2C-TFM |
| Drug class | Selective serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen; Antidepressant |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C14H18F3NO2 |
| Molar mass | 289.298 g·molâ1 |
| 3D model (JSmol) | |
| |
| |
Interactions
Pharmacology
Pharmacodynamics
LPH-5 acts as a potent partial agonist of the serotonin 5-HT2A receptor (Ki = 1.3 nM, EC50 = 2.1â25 nM, Emax = 56â94%).[3][6] It shows 10- to 100-fold selectivity for the 5-HT2A receptor over the serotonin 5-HT2B and 5-HT2C receptors in terms of affinity and activational potency.[3] Along with related compounds like 25CN-NBOH, DMBMPP, and TGF-8027, LPH-5 is said to be one of the few truly selective serotonin 5-HT2A receptor agonists.[1][2][3][7]
The drug robustly induces the head-twitch response as well as persistent and robust antidepressant-like effects in rodents.[3] Owing to its high selectivity for the serotonin 5-HT2A receptor, LPH-5 is expected to avoid the cardiac and other risks of serotonin 5-HT2B receptor activation.[8]
Chemistry
Analogues
LPH-5's analogue LPH-48 is likewise a selective serotonin 5-HT2A receptor agonist and psychedelic with similar characteristics.[9][10] However, this drug has a shorter duration of action than LPH-5.[10] As with LPH-5, LPH-48 is also under development by Lophora for potential medical use.[9][10]
Another analogue of LPH-5 is 2T-2CTFM-3PIP (2-thio-LPH-5).[6]
History
LPH-5 was patented in 2021[6] and was first described in the scientific literature by Emil Märcher-Rørsted and colleagues in 2024.[2] These researchers are affiliated with the Danish pharmaceutical company Lophora.[2] In late 2025, LPH-5 was suggested as a possible alternative and replacement of DOI for use in scientific research.[11]
Society and culture
Legal status
Canada
LPH-5 is not an explicitly controlled substance in Canada as of 2025.[12] However, as a derivative of 2Cs, it might fall under phenethylamine blanket-ban language, although as a cyclized phenethylamine this is unclear.[12]
United States
LPH-5 is not an explicitly controlled substance in the United States.[13] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
Research
LPH-5 is under development by Lophora and Atai Beckley (formerly Atai Life Sciences and Beckley Psytech) for the potential treatment of major depressive disorder.[4][5] As of May 2025, it is in phase I clinical trials for this indication.[4][5][14][15][16]